Aug 26, 2025 7:00am EDT Unicycive Therapeutics to Participate in Upcoming Investor Events in September
Aug 18, 2025 7:05am EDT Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease
Aug 14, 2025 7:00am EDT Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
Jul 24, 2025 8:00am EDT Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology
Jul 08, 2025 8:30am EDT Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Jul 07, 2025 7:00am EDT Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
Jun 30, 2025 7:05am EDT Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Jun 10, 2025 6:00am EDT Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
